FDA orders warning labels on GLP-1 drugs for rare risk of vision loss

Mint leads with a patient-focused explanation of what users should know, citing the FDA’s multi-trial analysis and framing the warning around incidence findings.

NDTV emphasizes the “new warning labels” and focuses on alerting patients and clinicians to the risk of rare blindness from NAION.

CNBC foregrounds the FDA warning tied to widely known GLP-1 weight-loss brands, naming drugs like Wegovy and Zepbound and stressing the rare eye-condition risk.

The Hindu highlights the medical detail by naming NAION, describing its potential for significant vision loss, and stating it has been reported with all GLP-1 drugs.

Free Malaysia Today stresses the regulatory requirement and the expectation that labeling must warn about a potentially increased risk of a rare, serious permanent vision-loss condition.

Slashdot, via an NBC News quote, leads with an accessible description of NAION and includes added background that FDA could not identify a mechanism.

ZeroHedge leads with a strong framing (“consider discontinuing”) and also includes extensive numbers from FDA analyses and comparisons, plus a detailed look at labeling language placement.

CBS News keeps the framing straightforward by leading with the FDA announcement that GLP-1 weight-loss drugs must include a potential increased vision-loss warning.

Sky News (UK) leads with the UK readership-relevant point that companies must add a warning label, naming major weight-loss brands and emphasizing FDA’s order.

CBS News leads with the FDA’s warning and frames it as a rare vision-loss side effect tied to GLP-1 brands such as Ozempic and Wegovy.

Gizmodo leads by asserting regulators found a consistent link and frames it as an FDA order for a new warning for Ozempic and other GLP-1s.

The Hill leads with the FDA warning and explains NAION using the “eye stroke” description, focusing on the regulator’s requirement for patients and providers to be warned.

The New York Post foregrounds the headline hook about new warning labels over an incurable blindness condition, using a cautionary tone.

The Independent foregrounds the FDA’s addition of a rare vision-loss warning for widely used drugs like Ozempic, framing it as a new patient-safety notice.

The Independent frames the story as the FDA requiring GLP-1 makers to add a major change to warning labels.

Quartz emphasizes that the warning is required for all GLP-1 weight-loss drugs, explicitly tying it to NAION and listing major brand names.

NBC News leads on the FDA ordering new warning labels over a rare eye condition linked to sudden blindness, presenting the action as the main event.

NDTV focuses on the obesity-drug context, naming specific GLP-1 brands and stating the FDA will require warnings about increased NAION risk.

MarketWatch - Technology leads with the idea that studies show an elevated risk for NAION among people taking GLP-1 medications.

Business of Fashion highlights the FDA’s label requirement for GLP-1 receptor agonist therapies and ties it directly to NAION safety labeling.

The Financial Times leads with the regulator’s directive to drugmakers and highlights the risk of rare eye conditions that can cause permanent vision loss.

Euronews foregrounds that the FDA requires manufacturers to update safety labels, describing the potential for permanent vision loss from a rare condition.

MedPage Today leads with the FDA’s safety warning move, centering on NAION and describing it as rare but potentially blinding in tone and focus.

STAT News uses the phrasing ‘eye stroke’ to characterize the rare eye condition risk, framing the FDA warning as a patient-safety alert.